Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer

Gastric Cancer

Volumn 9, Issue 3, 2006, Pages 203-207

  Ueda, Shinya ^a   Hironaka, Shuichi ^a   Boku, Narikazu ^a   Fukutomi, Akira ^a   Yoshino, Takayuki ^a   Onozawa, Yusuke ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

CDDP; CPT 11; Gastric cancer; Prior chemotherapy

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; INFECTION COMPLICATION; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33748917254     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-006-0379-2     Document Type: Article

References (19)

1. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41
2. S Pyrhonen T Kuitunen M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 91
3. B Glimelius K Hoffmann U Haglund O Nyren PO Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 90
4. Scheithauer W, Komek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial (abstract). Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, Koln, Germany; 1995. p. 68
5. T Taguchi Y Sakata R Kanamaru M Kurihara M Suminaga J Ota 1998 Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group A) Jpn J Cancer Chemother 25 1915 24
6. M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota 1999 A late phase II clinical study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group B) Jpn J Cancer Chemother 26 1487 96
7. I Hyodo A Ohtsu K Shirao Y Miyata H Saito T Taguchi 2002 Late phase II study of paclitaxel (BMS-181339) in patients with advanced/recurrent gastric cancer; a Japanese Cooperative Study Group trial (group A) The 38th annual meeting of Japan Society for Cancer Therapy 35 443
8. K Futatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada 1994 Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer Jpn J Cancer Chemother 21 1033 38
9. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrumidine anticancer drug S-1 (1∈M tegafur-0.4∈M gimestat-1∈M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 20
10. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 23
11. JA Ajani J Baker PW Pisters L Ho PF Mansfield BW Feig 2002 CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma Cancer 94 641 6
12. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO offset/Publication No. 48; 1979
13. M Kambe A Wakui I Nakao 1993 A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer Proc Am Soc Clin Oncol 12 198
14. CH Kohne P Thuss-Patience R Catane H Klein T Peretz P Preusser 1999 Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer (abstract) Proc Am Soc Clin Oncol 18 258a
15. JA Ajani J Baker PW Pisters L Ho PF Mansfield BW Feig 2002 Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma Oncol 16 16 18
16. T Hamaguchi A Ohtsu I Hyodo Y Arai H Takiuchi H Fujii 2004 A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: The Japan Clinical Oncology Group trial (JCOG0109) Proc Am Soc Clin Oncol 22 4071
17. ST Kim WK Kang JH Kang KW Park J Lee SH Lee 2005 Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer Br J Cancer 92 1850 4
18. T Arai T Hamaguchi K Shirao Y Shimada Y Yamada K Muro 2003 Weekly paclitaxel in patients with heavily treated advanced pastric cancer Proc Am Soc Clin Oncol 22 321
19. SH Park WK Kang HR Lee J Park KE Lee SH Lee 2004 Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Am J Clin Oncol 27 477 80